Related Experiment Video
Updated: Mar 29, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
Samantha Turnbull1, Emma J West2, Karen J Scott3
1Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS2 9JT, UK. s.j.turnbull@leeds.ac.uk.
Abstract:
The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do we move forward into the clinical setting and translate something which has such potential into meaningful clinical outcomes? Here, we review how the field of oncolytic virotherapy has developed thus far and what the future may hold.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
Treatment Resistent Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

